In vitro experiments showed that these reprogrammed A10-3.2/si-CAT-1/3WJ-NDs displayed good CEUI, enhanced tumor cell specific targeting, and increased intracellular delivery of siCAT-1 to suppress tumor growth. This evidence concerns the gene SLC7A1 and neoplasm.